Autoimmunity: Twenty years in the Fas lane

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5097-5100

  Ramaswamy, Madhu ^a   Siegel, Richard M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; AUTOSOMAL DOMINANT INHERITANCE; GENE MUTATION; HUMAN; LYMPHADENOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD95; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHATIC DISEASES; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84869860018     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202833     Document Type: Review

References (62)

1. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
2. Cohen, P. L., and R. A. Eisenberg. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9: 243-269.
3. Mountz, J. D., T. Zhou, J. Eldridge, K. Berry, and H. Blüthmann. 1990. Transgenic rearranged T cell receptor gene inhibits lymphadenopathy and accumulation of CD4-CD8-B220+ T cells in lpr/lpr mice. J. Exp. Med. 172: 1805-1817.
4. Kelley, V. E., and J. B. Roths. 1985. Interaction of mutant lpr gene with background strain influences renal disease. Clin. Immunol. Immunopathol. 37: 220-229. (Pubitemid 15239408)
5. Watanabe-Fukunaga, R., C. I. Brannan, N. Itoh, S. Yonehara, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148: 1274-1279.
6. Nagata, S. 2004. Early work on the function of CD95, an interview with Shige Nagata. Cell Death Differ. 11(Suppl. 1): S23-S27. (Pubitemid 39136795)
7. Watanabe, T., Y. Sakai, S. Miyawaki, A. Shimizu, O. Koiwai, and K. Ohno. 1991. A molecular genetic linkage map of mouse chromosome 19, including the lpr, Ly-44, and Tdt genes. Biochem. Genet. 29: 325-335.
8. Chu, J. L., J. Drappa, A. Parnassa, and K. B. Elkon. 1993. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J. Exp. Med. 178: 723-730. (Pubitemid 23218222)
9. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178. (Pubitemid 24006113)
10. Lynch, D. H., M. L. Watson, M. R. Alderson, P. R. Baum, R. E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C. A. Smith, K. Hunter, et al. 1994. The mouse Fasligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1: 131-136.
11. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976. (Pubitemid 24106378)
12. Sneller, M. C., S. E. Straus, E. S. Jaffe, J. S. Jaffe, T. A. Fleisher, M. Stetler-Stevenson, and W. Strober. 1992. A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J. Clin. Invest. 90: 334-341.
13. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, and J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946.
14. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
15. Dhein, J., H. Walczak, C. Bäumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441.
16. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444.
17. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I. A. Roberts, K. M. Debatin, A. Fischer, and J. P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349.
18. Drappa, J., A. K. Vaishnaw, K. E. Sullivan, J. L. Chu, and K. B. Elkon. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335: 1643-1649. (Pubitemid 26392729)
19. Sneller, M. C., J. Wang, J. K. Dale, W. Strober, L. A. Middelton, Y. Choi, T. A. Fleisher, M. S. Lim, E. S. Jaffe, J. M. Puck, et al. 1997. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89: 1341-1348. (Pubitemid 27079998)
20. Infante, A. J, H. A. Britton, T. DiNapoli, L. A Middelton, M. J. Lenardo, C. E. Jackson, J. Wang, T. Fleisher, S. E. Straus, and J. M. Puck. 1998. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J. Pediatr. 133: 629-633. (Pubitemid 28521211)
21. Bettinardi, A., D. Brugnoni, E. Quiròs-Roldan, A.Malagoli, S. La Grutta, A. Correra, and L. D. Notarangelo. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 89: 902-909. (Pubitemid 27121283)
22. Oliveira, J. B., J. J. Bleesing, U. Dianzani, T. A. Fleisher, E. S. Jaffe, M. J. Lenardo, F. Rieux-Laucat, R. M. Siegel, H. C. Su, D. T. Teachey, and V. K. Rao. 2010. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 116:e35-e40.
23. Holzelova, E., C. Vonarbourg, M. C. Stolzenberg, P. D. Arkwright, F. Selz, A. M. Prieur, S. Blanche, J. Bartunkova, E. Vilmer, A. Fischer, et al. 2004. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N. Engl. J. Med. 351: 1409-1418. (Pubitemid 39288167)
24. Kischkel, F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H. Krammer, and M. E. Peter. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579-5588.
25. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
26. Boldin, M. P., T. M. Goncharov, Y. V. Goltsev, and D. Wallach. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815.
27. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J. D. Bretz, M. Zhang, R. Gentz, et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827. (Pubitemid 26193033)
28. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer, M. E. Peter, F. Li, et al. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1687. (Pubitemid 28119121)
29. Holler, N., A. Tardivel, M. Kovacsovics-Bankowski, S. Hertig, O. Gaide, F. Martinon, A. Tinel, D. Deperthes, S. Calderara, T. Schulthess, et al. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23: 1428-1440. (Pubitemid 36177050)
30. O' Reilly, L. A., L. Tai, L. Lee, E. A. Kruse, S. Grabow, W. D. Fairlie, N. M. Haynes, D. M. Tarlinton, J. G. Zhang, G. T. Belz, et al. 2009. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663.
31. Wang, L., J. K. Yang, V. Kabaleeswaran, A. J. Rice, A. C. Cruz, A. Y. Park, Q. Yin, E. Damko, S. B. Jang, S. Raunser, et al. 2010. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 17: 1324-1329.
32. Siegel, R. M., J. R. Muppidi, M. Sarker, A. Lobito, M. Jen, D. Martin, S. E. Straus, and M. J. Lenardo. 2004. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167: 735-744. (Pubitemid 39565153)
33. Algeciras-Schimnich, A., L. Shen, B. C. Barnhart, A. E. Murmann, J. K. Burkhardt, and M. E. Peter. 2002. Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22: 207-220. (Pubitemid 33144269)
34. Muppidi, J. R., and R. M. Siegel. 2004. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat. Immunol. 5: 182-189. (Pubitemid 38208360)
35. Feig, C., V. Tchikov, S. Schütze, and M. E. Peter. 2007. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26: 221-231. (Pubitemid 46094713)
36. Chakrabandhu, K., Z. Hérincs, S. Huault, B. Dost, L. Peng, F. Conchonaud, D. Marguet, H.-T. He, and A.-O. Hueber. 2007. Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 26: 209-220. (Pubitemid 46094712)
37. Siegel, R. M., J. K. Frederiksen, D. A. Zacharias, F. K. Chan, M. Johnson, D. Lynch, R. Y. Tsien, and M. J. Lenardo. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288:2354-2357. (Pubitemid 30448157)
38. Varfolomeev, E. E., M. Schuchmann, V. Luria, N. Chiannilkulchai, J. S. Beckmann, I. L. Mett, D. Rebrikov, V. M. Brodianski, O. C. Kemper, O. Kollet, et al. 1998. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9: 267-276. (Pubitemid 28400040)
39. Zhang, J., D. Cado, A. Chen, N. H. Kabra, and A. Winoto. 1998. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296-300.
40. Kabra, N. H., C. Kang, L. C. Hsing, J. Zhang, and A.Winoto. 2001. T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc. Natl. Acad. Sci. USA 98: 6307-6312. (Pubitemid 32488235)
41. Chun, H. J., L. Zheng, M. Ahmad, J. Wang, C. K. Speirs, R. M. Siegel, J. K. Dale, J. Puck, J. Davis, C. G. Hall, et al. 2002. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399.
42. Zhang, H., X. Zhou, T. McQuade, J. Li, F. K. Chan, and J. Zhang. 2011. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471: 373-376.
43. Kaiser, W. J., J. W. Upton, A. B. Long, D. Livingston-Rosanoff, L. P. Daley-Bauer, R. Hakem, T. Caspary, and E. S. Mocarski. 2011. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368-372.
44. Oberst, A., and D. R. Green. 2011. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat. Rev. Mol. Cell Biol. 12: 757-763.
45. Oberst, A., C. P. Dillon, R. Weinlich, L. L. McCormick, P. Fitzgerald, C. Pop, R. Hakem, G. S. Salvesen, and D. R. Green. 2011. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363-367.
46. Peter, M. E., R. C. Budd, J. Desbarats, S. M. Hedrick, A. O. Hueber, M. K. Newell, L. B. Owen, R. M. Pope, J. Tschopp, H. Wajant, et al. 2007. The CD95 receptor: apoptosis revisited. Cell 129: 447-450. (Pubitemid 46660984)
47. Alderson, M. R., R. J. Armitage, E. Maraskovsky, T. W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D. H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178: 2231-2235. (Pubitemid 23344883)
48. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
49. Kreuz, S., D. Siegmund, J. J. Rumpf, D. Samel, M. Leverkus, O. Janssen, G. Häcker, O. Dittrich-Breiholz, M. Kracht, P. Scheurich, and H. Wajant. 2004. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 166: 369-380. (Pubitemid 39031240)
50. Desbarats, J., and M. K. Newell. 2000. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6: 920-923. (Pubitemid 30644752)
51. Riou, C., B. Yassine-Diab, J. Van grevenynghe, R. Somogyi, L. D. Greller, D. Gagnon, S. Gimmig, P. Wilkinson, Y. Shi, M. J. Cameron, et al. 2007. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD41 central memory T cells. J. Exp. Med. 204: 79-91. (Pubitemid 46148759)
52. Ramaswamy, M., A. C. Cruz, S. Y. Cleland, M. Deng, S. Price, V. K. Rao, and R. M. Siegel. 2011. Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains. Cell Death Differ. 18: 712-720.
53. Bouillet, P., J. F. Purton, D. I. Godfrey, L. C. Zhang, L. Coultas, H. Puthalakath, M. Pellegrini, S. Cory, J. M. Adams, and A. Strasser. 2002. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415: 922-926. (Pubitemid 34174755)
54. Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, and P. Marrack. 2002. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16: 759-767. (Pubitemid 34786475)
55. Hughes, P. D., G. T. Belz, K. A. Fortner, R. C. Budd, A. Strasser, and P. Bouillet. 2008. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 28: 197-205. (Pubitemid 351215234)
56. Hutcheson, J., J. C. Scatizzi, A. M. Siddiqui, G. K. Haines, III, T. Wu, Q. Z. Li, L. S. Davis, C. Mohan, and H. Perlman. 2008. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 28: 206-217. (Pubitemid 351215233)
57. Chen, L., S. M. Park, A. V. Tumanov, A. Hau, K. Sawada, C. Feig, J. R. Turner, Y. X. Fu, I. L. Romero, E. Lengyel, and M. E. Peter. 2010. CD95 promotes tumour growth. Nature 465: 492-496.
58. Trauth, B. C., C. Klas, A. M. Peters, S. Matzku, P. Möller, W. Falk, K. M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305. (Pubitemid 19196649)
59. Stranges, P. B., J. Watson, C. J. Cooper, C. M. Choisy-Rossi, A. C. Stonebraker, R. A. Beighton, H. Hartig, J. P. Sundberg, S. Servick, G. Kaufmann, et al. 2007. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26: 629-641. (Pubitemid 46756349)
60. Hao, Z., G. S. Duncan, J. Seagal, Y. W. Su, C. Hong, J. Haight, N. J. Chen, A. Elia, A. Wakeham, W. Y. Li, et al. 2008. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity 29: 615-627.
61. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809. (Pubitemid 23261761)
62. Ramaswamy, M., M. Deng, and R. M. Siegel. 2011. Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases. Nat Rev Rheumatol 7: 152-160.